Results 161 to 170 of about 10,894,164 (293)

IMARINE - Virtual Research Environments Activity Report

, 2012
Virtual Research Environments are among the main products the iMarine project is requested to deliver in order to serve the needs of the Ecosystem Approach Community of Practice. The deployment and operation of a Virtual Research Environment is a task involving the exploitation of technologies that have been developed as well as the development of new ...
Ellenbroek A., Candela L., Pagano P.
openaire   +3 more sources

Insights into a long life without cancer: The case of the bowhead whale

Molecular Oncology, EarlyView.
Long‐lived, large‐bodied organisms have evolved powerful anticancer mechanisms that preserve cellular and tissue integrity across extended lifespans. A recent study by Firsanov et al. shows that greater genome stability is a key factor underlying the remarkable longevity and cancer resistance of one such species, the bowhead whale.
Inés Paniagua, Johanna A. Joyce
wiley   +1 more source

Strengthening Pharmacoepidemiology in a Changing Research Environment: The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). [PDF]

Pharmacoepidemiol Drug Saf
Kurz X, Cohet C, Perez-Gutthann S, Rao S, Gardarsdottir H.   +4 more
europepmc   +1 more source

Impact of COVID-19 restrictions on the research environment and motivation of researchers in Japan. [PDF]

Prog Disaster Sci, 2020
Miki Y, Chubachi N, Imamura F, Yaegashi N, Ito K.   +4 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Of maps, Crown copyright, research and the environment [PDF]

, 2008
Derclaye, Estelle
core   +1 more source

Checkpoint blockade and the stem‐like T cell trade‐off

Molecular Oncology, EarlyView.
Stem‐like T cells are key to the success of programmed cell death protein 1 (PD1) blockade, as they sustain long‐term anti‐tumor response by continuously generating effector CD8+ T cells. However, how these cells are maintained in cancer is not fully understood. Hor et al.
Julie M. Mazet, Johanna A. Joyce
wiley   +1 more source

Artificial intelligence will change the research environment in dental medicine dramatically: will algorithms replace literature reviews in the near future? [PDF]

Dentomaxillofac Radiol
Bornstein MM, Staedler YM, Cattin PC.
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Pursue the nature of science: Advocate for a better research environment. [PDF]

Innovation (Camb)
Dai J.
europepmc   +1 more source